0013747 2026 RIV NL eng J
Šťastná Marková, Markéta - Pecherková, Pavla - Němečková, Šárka - Kryštofová, Jitka - Vaníková, Šárka - Vydra, Jan - Roubalová, Kateřina^G
Interferon gamma release assay has potential in the prediction of chronic graft-versus-host disease in recipients of myeloablative allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis.
Transplant immunology. Vol. 88, no. February (2025) art. no. 102166. ISSN 0966-3274
Grant: Ministerstvo zdravotnictví NU22-E-138
Institucionální podpora: RVO:00023736
Klíčová slova: AML * GVHD prophylaxis * MDS
Cite Score: 2.800, rok: 2024; SJR: 0.458, rok: 2024; IF: 1.4, rok: 2024
DOI: 10.1016/j.trim.2024.102166

Anotace: The rate of immune reconstitution after allogeneic hematopoietic stem cell transplantation (allo-HSCT) plays the principal role in the development of serious post-transplant complications. However, the post-transplantation course has a significant impact on shaping the immune system of the recipient, per se, thus representing risk factors for subsequent unfavorable outcomes. The predictive power of an interferon gamma (IFNγ) release assay (IGRA) on graft-versus-host disease (GVHD) or hematological relapse in recipients of allo-HSCT treated with post-transplantation cyclophosphamide and the impact of these complications on the restoration of cellular immune responsiveness was evaluated.